Biothera presents new Impirme PGG data at SITC meeting
Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »